The names and details of the Company’s Directors at the date of this report are set out below. All Directors except Andreas Kluge served on the Board for the full financial year ended 31 December 2023. Andreas Kluge took leave of absence from his role as Non-Executive Director from 29 March to 29 September 2023, inclusive.1
Appointed Non-Executive Director and Chairman, 17 September 2017
Skills and experience
Mr McCann has extensive Board experience with some of Australia’s most recognised companies. He is a former corporate lawyer and experienced Chairman and Director of listed private and government companies, and government agencies.
In his roles as Chairman of the Board and Chair of the People, Culture, Nomination and Remuneration Committee, his experienced leadership promotes a cohesive, constructive challenge and oversight environment. Mr McCann’s expertise in shaping culture (including through organisational and remuneration design), public policy, social performance and stakeholder engagement, enables him to bring valuable insights in these areas.
Mr McCann received a Bachelor of Arts and a Bachelor of Law (Honours) from Sydney University, a Master of Law from Harvard University and has been awarded an honorary Doctor of Laws from Sydney University. He is a Life Fellow of the Australian Institute of Company Directors.
Career summary
Previously, Mr McCann served as Chairman of Macquarie Group and Macquarie Bank Limited (from December 1996 to March 2016), Origin Energy Limited (from January 2000 to October 2013) and the Sydney Harbour Federation Trust (from June 2001 to June 2010 and from June 2015 to June 2018). He was also previously a Director of Bluescope Steel Ltd (from May 2002 to April 2013) and E&P Financial Group Limited (from February 2020 to November 2021). He was also a Director of the U.S. Studies Centre at the University of Sydney (from June 2010 to June 2020) and was a Trustee of the Sydney Opera House (from January 2018 to December 2023). Currently, Mr McCann is a Member of Champions of Change Founding Group (since April 2010), Chairman of Sydney Harbour Foundation Management (since August 2015), Chairman of China Matters (since November 2018), a Director of Haydn Ensemble (since December 2020), and Chair and Board Advisor of Blueprint Institute (since June 2022).
Mr McCann practised as a commercial lawyer as a partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. He was made an Officer of the Order of Australia for services to business, corporate governance and gender equality in January 2020.
Co-Founder. Appointed Managing Director and Group Chief
Executive Officer, 3 January 2017
Skills and experience
Dr Behrenbruch has more than two decades of radiopharmaceuticals experience and a strong track record in global healthcare and biotechnology entrepreneurship and technology commercialisation. He brings a unique blend of technical expertise and executive leadership to guide Telix as it enters the next stage of its strategy.
Dr Behrenbruch has a strong focus on purpose and values-leadership, and is well versed in all aspects of running a publicly listed company as both CEO and Director in the U.S. and Australia.
Dr Behrenbruch holds a DPhil (PhD) in biomedical engineering from the University of Oxford, an executive MBA jointly awarded from New York University, HEC Paris and the London School of Economics (TRIUM Program) and a Juris Doctor from the University of Melbourne. He is a Fellow of Engineers Australia in the management and biomedical colleges and a Graduate of the Australian Institute of Company Directors.
Career summary
Previously, Dr Behrenbruch served as Chief Executive Officer at Mirada Solutions (now Mirada Medical Limited) (from July 2001 to December 2002), President at CTI Molecular Imaging (now Siemens Healthcare) (from August 2003 to September 2006), Chief Executive Officer at Fibron Technologies, Inc. (from June 2008 to December 2011) and Chief Executive Officer at ImaginAb, Inc. (from October 2007 to February 2015). He served as a Director at Siemens Molecular Imaging Ltd (from May 2005 to September 2006), Momentum Biosciences LLC (from July 2007 to June 2009), Radius Health Ltd (now Adaptix Ltd) (from May 2009 to February 2011), Factor Therapeutics Limited (ASX: FTT) (from October 2015 to May 2021) and Amplia Therapeutics Limited (ASX: ATX) (from May 2016 to February 2020). Dr Behrenbruch was the Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre) (from October 2012 to July 2014).
Co-Founder. Appointed Executive Director, 3 January 2017
Transitioned to Non-Executive Director, 2 June 2020
Skills and experience
Dr Kluge’s depth of clinical research and development experience in radiochemistry, molecular imaging and clinical development is highly valued by the Board. He brings a critical mind to the requirements of clinical development of novel radionuclide-based products and devices to enable successful clinical trials and commercialisation of Telix’s pipeline assets.
Dr Kluge received his doctorate degree in Medicine from the Free University of Berlin. He is a registered physician and the author of numerous patents and publications in the field of nuclear medicine, neurology, infection and immunology.
(Continued)
Career summary
Dr Kluge is a Founder, General Manager and Medical Director of ABX-CRO Advanced Pharmaceutical Services GmbH (since August 2002), a full-service Contract Research Organisation (CRO) for Phase I-III biological, radiopharmaceutical and anticancer trials based in Dresden, Germany. He was also a Founder and founding CEO of ABX GmbH (www.abx.de) (from September 1996 to July 2002), one of the leading manufacturers of radiopharmaceutical precursors globally.
Appointed Non-Executive Director, 17 September 2017
Skills and experience
Dr Nelson’s vast experience in the investment community, including in life sciences, brings a sound investment perspective to the implementation of Telix's strategy and makes him a highly valued member of the Telix Board.
Dr Nelson received his BSc from the University of Melbourne, his MPhil from the University of Cambridge and his PhD from the University of Melbourne.
Career summary
Dr Nelson has served as Chairman of the Caledonia Investments Group (since January 2012) and as a Director of The Caledonia Foundation (since August 2002). He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group (from February 1992 to January 2012). Dr Nelson has served as Chairman of Art Exhibitions Australia (since 2019), Director of the Mindgardens Neuroscience Network (since February 2018), Governor of the Florey Neurosciences Institute (since October 2007), and Director of Kaldor Public Art Projects (since October 2005).
Appointed Non-Executive Director, 31 March 2022
Skills and experience
Ms Olson brings a depth of experience in commercialisation and corporate strategy in oncology, including in the radiopharmaceuticals sector, which the Telix Board values highly as it oversees the implementation of the Company’s strategy.
Ms Olson received her MBA and BSB from the University of St. Thomas and BSB from the University of Minnesota.
Career summary
Ms Olson's most recent executive role was with Cardinal Health, the largest provider of radiopharmaceuticals in the U.S.. As President of Cardinal Health Nuclear & Precision Health Solutions (from July 2013 to October 2021), overseeing Cardinal’s radiopharmaceutical manufacturing and nuclear pharmacy network, she led a significant business transformation that increased market share and profit growth.
(Continued)
Prior to Cardinal Health, Ms Olson served as President of NaviMed (from August 2011 to July 2013), as Vice President Diagnostics at Eli Lilly and Company (from November 2009 to July 2011), and as President and Chief Executive Officer at Roche Diagnostics Corporation (from June 2005 to May 2008). Previously she was a Director at Asuragen, Inc (from August 2016 to March 2021) and at BioTelemetry, Inc. (from February 2019 to February 2021). She currently serves as a Director of Castle Biosciences, Inc. (since April 2021), an Advisory Board member at Langham Logistics (since August 2021), a Director at Education and Research Foundation, Nuclear Medicine & Molecular Imaging (since April 2022) and a Partner at Trusted Health Advisors (since August 2023).
Appointed Non-Executive Director, 19 June 2018
Skills and experience
Ms Skinner has significant financial acumen, accounting and auditing expertise, with a strong understanding of risk management compliance frameworks and control oversight. Her listed company experience and expertise in capital management and corporate development enable her to challenge management constructively.
Ms Skinner is a Fellow of both Chartered Accountants Australia & New Zealand and the Australian Institute of Company Directors. She received her Bachelor of Commerce from the University of New South Wales.
Career summary
Ms Skinner is a qualified chartered accountant with extensive experience in auditing, accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004.
She has served as an independent Non-Executive Director of QBE Insurance Group Limited (since October 2014) and a Director of Create Foundation Limited (since June 2004). She also served as a Director of HSBC Bank Australia Limited (from April 2017 to April 2023).
Appointed Company Secretary, 5 December 2022
Career summary
Ms Ryan has 18 years’ experience in legal and governance roles, including with ASX-200 companies. Previously, she was General Counsel – Governance, Corporate and Commercial at Orora Limited. Ms Ryan has also been Senior Legal Counsel and Alternate Company Secretary at Australian Pharmaceutical Industries Limited (acquired by Wesfarmers Limited). Ms Ryan began her career as a lawyer with law firm Ashurst (formerly Blake Dawson).
- Telix ASX disclosure 29 March 2023.